Céline Lepère

Céline Lepère

Auto-generated profile, based on publicly available information

Céline Lepère

Hôpital Européen Georges Pompidou Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology Paris

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Medicine
Verified
Journal Article
Open access
BBBertrand Brieau
Bertrand Brieau
CLCéline Lepère
Céline Lepère
TWThomas Walter
Thomas Walter
TLThierry Lecomte
Thierry Lecomte
RGRosine Guimbaud
Rosine Guimbaud
RCRomain Coriat
Romain Coriat
Neuroendocrine carcinomas (NEC) of the anus or the rectum are a rare disease, accounting for less than 1% of all digestive malignancies. Most are metastatic at diagnosis and treated with a platinum-based chemotherapy. No guidelines for localized tumors exist. The purpose of this study was to describe the characteristics of anorectal localized NEC, their management and their outcomes. We retrospectively reviewed patients from 11 French centers with anorectal localized NEC. We compared 2 therapeutic managements: surgery (group A) versus chemotherapy with or without radiation (group B). Progression-free survival (PFS) and overall survival (OS) were estimated with the Kaplan–Meier method. A total of 24 patients were identified with a median follow-up of 25 months (3–60 months). Median age was 63 years old and 17 had a rectal tumor (71%). Mean Ki-67 was 72% (range: 20–100), and 75% of the tumors had a high proliferative index (Ki-67 > 50%). Global PFS and OS were 13.1 and 44.1 months, respectively. Thirty-seven percent of patients were in group A and 63% in group B. There was no difference between group A and group B, whether in terms of PFS (13.0 months vs. 13.2 months, P = 0.75) or OS (49.1 months vs. 39.2 months, P = 0.42). In patients with anorectal localized NEC, chemotherapy with or without radiation obtained a similar outcome as surgery and this conservative approach could be deemed a reasonable option.

7 December 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EBEmilie Baron
Emilie Baron
CSCatherine Szymanski
Catherine Szymanski
HHHélène Hergault
Hélène Hergault
CLCéline Lepère
Céline Lepère
ODOlivier Dubourg
Olivier Dubourg
NMNicolas Mansencal
Nicolas Mansencal
Background: The development of carcinoid heart disease (CaHD) is still relatively unclear. It is difficult to define an optimal follow‐up for patients without any cardiac involvement at baseline. The aim of this study was to assess the prevalence and natural history of CaHD by annual echocardiographic examinations. Methods and Results: We studied 137 consecutive patients (61±12 years, 53% men) with proven digestive endocrine tumor and carcinoid syndrome between 1997 and 2017. All patients underwent serial conventional transthoracic echocardiographic studies. Right‐sided and left‐sided CaHD were systematically assessed. We used a previous validated echocardiographic scoring system of severity for the assessment of CaHD. An increase of 25% of the score was considered to be significant. Mean follow‐up was 54±45 months. Prevalence of CaHD was 27% at baseline and 32% at 5‐year follow‐up. Disease progression was reported in 28% of patients with initial CaHD followed up for >2 years (n=25). In patients without any cardiac involvement at baseline, occurrence of disease was 21%. CaHD occurred >5 years from the initial echocardiographic examination in 42% of our cases, especially in patients presenting with new recurrence of a digestive endocrine tumor. An increase of urinary 5‐hydroxyindoleacetic acid by 25% during follow‐up was identified as an independent predictor of CaHD occurrence during follow‐up (hazard ratio [HR], 5.81; 95% CI, 1.19–28.38; P =0.03), as well as a maximum value of urinary 5‐hydroxyindoleacetic acid >205 mg/24 h during follow‐up (HR, 8.41; 95% CI, 1.64–43.07; P =0.01). Conclusions: Our study demonstrates that in patients without initial CaHD, cardiac involvement may occur late and is related to serotonin. Our data emphasize the need for cardiologic follow‐up in patients with recurrence of the tumor process.

20 August 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
Aziz ZaananAziz Zaanan
Aziz Zaanan
EBElisabeth Sophie Bergen
Elisabeth Sophie Bergen
LELudovic Evesque
Ludovic Evesque
AMAurelia Meurisse
Aurelia Meurisse
PAPascal Artru
Pascal Artru
PLPierre Laurent-Puig
Pierre Laurent-Puig
Background: In RAS wild-type (WT) metastatic colorectal cancer (mCRC), preliminary data have suggested that circulating tumor DNA (ctDNA) may select patients for anti-EGFR rechallenge therapy. Methods: RASINTRO is a prospective nonrandomized study evaluating anti-EGFR rechallenge strategy in third and later line treatment in RAS/BRAF WT mCRC. Liquid biopsies for ctDNA analysis were collected before the first (C1) and second (C2) cycles of anti-EGFR rechallenge therapy. The primary endpoint was the progression-free survival (PFS) according to RAS/BRAF mutational status on ctDNA at C1. Results: Among 74 patients screened between November 2017 and March 2020, 62 were enrolled: median age, 66.1 years; median number of previous lines of therapy, 3; panitumumab or cetuximab rechallenge alone (66.2%) or with chemotherapy (33.8%); ctDNA RAS/BRAF status at C1, 42 WT (67.7%) and 20 mutated (32.3%). Median PFS (3.3 vs 1.9 months: hazard ratio (HR) = 0.43; P <.01) and overall survival (OS) (7.9 vs 4.9 months; HR = 0.46; P =.01) were significantly longer for patients with ctDNA RAS/BRAF WT vs mutated at C1. Among the 32 patients with ctDNA RAS/BRAF WT at C1 and available blood samples at C2, those who have experienced an early decrease of >50% in ctDNA concentration (n = 15) had a significantly longer median PFS (4.2 vs 2.8 months; HR = 0.39; P =.01) and OS (10.2 vs 4.2 months; HR = 0.39; P =.02). Conclusion: This study showed that anti-EGFR rechallenge therapy in refractory disease is more effective in patients with RAS/BRAF WT on ctDNA, and in those who experienced an early decrease of >50% in ctDNA concentration Trial Registration: ClinicalTrials.gov Identifier: NCT03259009.

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Julien TaiebJulien Taieb
Julien Taieb
CBChristophe Borg
Christophe Borg
TLThierry Lecomte
Thierry Lecomte
CLCéline Lepère
Céline Lepère
TCThierry Chatellier
Thierry Chatellier
OHOlivier Hermine
Olivier Hermine
3526 Background: Masitinib (MAS) is a selective inhibitor of c-Kit and mast cell function. Increased mast cell activity in the tumor microenvironment is linked to poor prognosis and a protumoral immune response in colorectal cancer (CRC). In vitro, MAS acts as a chemosensitizer of 5-fluorouracil and irinotecan in CRC cell lines. This trial evaluated MAS in combination with chemotherapies. We report here findings from the cohort receiving MAS + FOLFIRI. Methods: Patients (pts) with nonresectable, metastatic CRC after progression to first line treatment received MAS + FOLFIRI until progression, refusal or unacceptable toxicity. Patients previously treated with irinotecan were excluded. Phase 1 evaluated safety of the combination with Dose Limiting Toxicity (DLT) determining subsequent dose and recruitment. DLT was defined as grade 3 non hematological adverse event (AE) or any grade 4 AE related to MAS. Phase 2 evaluated efficacy. Results: Eighteen pts (50% with mutated KRAS) from 6 centers in France were tr...

12 December 2014 in Oncologie
Verified
Journal Article
Closed access
PDF file
SPS. Pernot
S. Pernot
OPOlivier Pellerin
Olivier Pellerin
NGN. Ghazzar
N. Ghazzar
JVJ. N. Vaillant
J. N. Vaillant
CLC. Lepère
C. Lepère
PRP. Rougier
P. Rougier
Les traitements locaux des métastases hépatiques (MH) des adénocarcinomes colorectaux (CCR) prennent une place de plus en plus importante dans les stratégies thérapeutiques des patients ayant des MH non résécables limitées ou prédominantes au foie. La chimiothérapie intraartérielle hépatique (CIAH) a démontré très tôt son efficacité. Sa combinaison avec des polychimiothérapies systémiques a permis de doubler les taux de réponse et d’augmenter les taux de résection secondaires et la survie des patients. L’efficacité des chimioembolisations (CE) et des radioembolisations (RE) a surtout été établie à partir d’études de phase II ou de phase III les ayant évaluées à des stades très avancés, où la survie sans progression et la survie globale étaient augmentées. La place de ces traitements à des stades plus précoces est en cours d’évaluation, et devrait permettre d’optimiser la prise en charge des patients avec MH. Ces traitements locaux doivent être aujourd’hui utilisés en combinaison avec des traitements systémiques efficaces et/ou des résections, et le choix des meilleures stratégies et protocoles doit être fait en RCP spécialisées. Local treatment of liver metastases (LM) of colorectal adenocarcinomas (CRC) has an emerging role in strategies of treatment for patients with limited or predominant unresectable LM. Hepatic intra-arterial chemotherapy (HIAC) demonstrated efficacy. Its combination with systemic chemotherapy allowed to double the response rate, and increased the rate of secondary resection and survival of patients. The effectiveness of chemoembolization (CE) and radio-embolization (RE) was primarily established from Phase II or Phase III evaluation of patients in very advanced stages, and progression-free survival and overall survival were increased. The role of these treatments at earlier stages is being evaluated and is expected to optimize the care of patients with LM. These local treatments must now be used in combination with effective systemic therapies, and/or resection, and the choice of the best strategies and protocols must be done in specialized team with collaboration of expert radiologist, nuclear medicine and oncologist.

1 March 2009 in Gastroentérologie Clinique Et Biologique
Verified
Journal Article
Closed access
MKM. Ksiaa
M. Ksiaa
JBJean-Baptiste Bachet
Jean-Baptiste Bachet
GDG. Declety
G. Declety
EME. Mitry
E. Mitry
CLC. Lepere
C. Lepere
PRP. Rougier
P. Rougier